Product Code: A02039
The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030. Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin, and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others). Some of the common fungal infections such as athlete's foot, fungal meningitis, ringworm, and other infections can be treated by antifungal drugs that work by killing the fungal cells, breaking the contents of the cells. These cells eventually leak out and result in the death of the cell, which also prevent the cell to grow further, thus preventing the infection.
Growth of the anti-fungal drugs market is majorly driven by alarming rise in prevalence of chronic diseases such as diabetes and tuberculosis drives the growth of the market. In addition, growth in incidence &prevalence rate of infectious diseases and growth in population of immuno-compromised (prone to infectious diseases) individuals contribute toward the growth of the market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period. Moreover, as per Centers for Disease Control and Prevention (CDC) estimates, there are roughly 46,000 cases of hospital-associated invasive candidiasis each year, a number that is increasing over the past two decades. Hospital-associated invasive candidiasis is among the most common bloodstream infections found in hospitalized patients, and is caused by Candida yeasts that generally dwell in the gut and on the skin with some problems. This disease has led to death in about 30% of patients with bloodstream infections. Most cases of candidiasis fungal infection occur in the U.S. and Canada. In states where blastomycosis is reportable, yearly incidence rates are approximately 1 to 2 cases per 100,000 people. In addition, surgein healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs are the factors that propel the market growth. Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region. By drug type, it is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. By therapeutic indication, it is classified into aspergillosis, dermatophytosis, candidiasis, and others. By infection type, the market is bifurcated into superficial and systemic antifungals.
By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2020, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
- Some of the major companies that operate in the global anti-fungal drugs market are Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novaris AG, Abbott Laboratories, GlaxosithKlinePlc, AstellasPharma Inc., Johnson & Johnson and Merz Pharma.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global anti-fungal drugs market to identify the prevailing opportunities.
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region & country-wise analysis is provided to understand the market trends and dynamics.
Key Market Segments
By Drug Class
- Azoles
- Fluconazole
- Voricanazole
- Posaconazole
- Clotrimazole
- Others
- Polyenes
- Allylamines
- Terbinafine
- Naftifine
- Others
- Others
- Echinocandins
- Caspofungin
- Micafungin
- Others
By Infection Type
- Superficial Antifungal Infections
- Systemic Antifungal Infections
By Therapeutic Indications
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Others
By Dosage Forms
By Region
- North America
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Hologic, Inc
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Siemens Medical Solutions USA, Inc.
- bioMerieux SA
- Abbott
- BD
- Cardinal Health, Inc.
- F. Hoffmann-La Roche Ltd
- General Electric Company
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Echinocandins
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Azoles
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Polyenes
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Allylamines
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
CHAPTER 5: ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Superficial Antifungal Infections
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Systemic Antifungal Infections
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
CHAPTER 6: ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Aspergillosis
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Dermatophytosis
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Candidiasis
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
CHAPTER 7: ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Oral
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Topical
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Others
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
CHAPTER 8: ANTIFUNGAL DRUGS MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Drug Class
- 8.2.3 North America Market size and forecast, by Infection Type
- 8.2.4 North America Market size and forecast, by Therapeutic Indications
- 8.2.5 North America Market size and forecast, by Dosage Forms
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by Drug Class
- 8.2.6.1.2 Market size and forecast, by Infection Type
- 8.2.6.1.3 Market size and forecast, by Therapeutic Indications
- 8.2.6.1.4 Market size and forecast, by Dosage Forms
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by Drug Class
- 8.2.6.2.2 Market size and forecast, by Infection Type
- 8.2.6.2.3 Market size and forecast, by Therapeutic Indications
- 8.2.6.2.4 Market size and forecast, by Dosage Forms
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by Drug Class
- 8.2.6.3.2 Market size and forecast, by Infection Type
- 8.2.6.3.3 Market size and forecast, by Therapeutic Indications
- 8.2.6.3.4 Market size and forecast, by Dosage Forms
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Drug Class
- 8.3.3 Europe Market size and forecast, by Infection Type
- 8.3.4 Europe Market size and forecast, by Therapeutic Indications
- 8.3.5 Europe Market size and forecast, by Dosage Forms
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by Drug Class
- 8.3.6.1.2 Market size and forecast, by Infection Type
- 8.3.6.1.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.1.4 Market size and forecast, by Dosage Forms
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by Drug Class
- 8.3.6.2.2 Market size and forecast, by Infection Type
- 8.3.6.2.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.2.4 Market size and forecast, by Dosage Forms
- 8.3.6.3 United Kingdom
- 8.3.6.3.1 Market size and forecast, by Drug Class
- 8.3.6.3.2 Market size and forecast, by Infection Type
- 8.3.6.3.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.3.4 Market size and forecast, by Dosage Forms
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by Drug Class
- 8.3.6.4.2 Market size and forecast, by Infection Type
- 8.3.6.4.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.4.4 Market size and forecast, by Dosage Forms
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by Drug Class
- 8.3.6.5.2 Market size and forecast, by Infection Type
- 8.3.6.5.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.5.4 Market size and forecast, by Dosage Forms
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by Drug Class
- 8.3.6.6.2 Market size and forecast, by Infection Type
- 8.3.6.6.3 Market size and forecast, by Therapeutic Indications
- 8.3.6.6.4 Market size and forecast, by Dosage Forms
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 8.4.3 Asia-Pacific Market size and forecast, by Infection Type
- 8.4.4 Asia-Pacific Market size and forecast, by Therapeutic Indications
- 8.4.5 Asia-Pacific Market size and forecast, by Dosage Forms
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 Japan
- 8.4.6.1.1 Market size and forecast, by Drug Class
- 8.4.6.1.2 Market size and forecast, by Infection Type
- 8.4.6.1.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.1.4 Market size and forecast, by Dosage Forms
- 8.4.6.2 China
- 8.4.6.2.1 Market size and forecast, by Drug Class
- 8.4.6.2.2 Market size and forecast, by Infection Type
- 8.4.6.2.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.2.4 Market size and forecast, by Dosage Forms
- 8.4.6.3 Australia
- 8.4.6.3.1 Market size and forecast, by Drug Class
- 8.4.6.3.2 Market size and forecast, by Infection Type
- 8.4.6.3.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.3.4 Market size and forecast, by Dosage Forms
- 8.4.6.4 India
- 8.4.6.4.1 Market size and forecast, by Drug Class
- 8.4.6.4.2 Market size and forecast, by Infection Type
- 8.4.6.4.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.4.4 Market size and forecast, by Dosage Forms
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by Drug Class
- 8.4.6.5.2 Market size and forecast, by Infection Type
- 8.4.6.5.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.5.4 Market size and forecast, by Dosage Forms
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by Drug Class
- 8.4.6.6.2 Market size and forecast, by Infection Type
- 8.4.6.6.3 Market size and forecast, by Therapeutic Indications
- 8.4.6.6.4 Market size and forecast, by Dosage Forms
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Drug Class
- 8.5.3 LAMEA Market size and forecast, by Infection Type
- 8.5.4 LAMEA Market size and forecast, by Therapeutic Indications
- 8.5.5 LAMEA Market size and forecast, by Dosage Forms
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by Drug Class
- 8.5.6.1.2 Market size and forecast, by Infection Type
- 8.5.6.1.3 Market size and forecast, by Therapeutic Indications
- 8.5.6.1.4 Market size and forecast, by Dosage Forms
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by Drug Class
- 8.5.6.2.2 Market size and forecast, by Infection Type
- 8.5.6.2.3 Market size and forecast, by Therapeutic Indications
- 8.5.6.2.4 Market size and forecast, by Dosage Forms
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by Drug Class
- 8.5.6.3.2 Market size and forecast, by Infection Type
- 8.5.6.3.3 Market size and forecast, by Therapeutic Indications
- 8.5.6.3.4 Market size and forecast, by Dosage Forms
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by Drug Class
- 8.5.6.4.2 Market size and forecast, by Infection Type
- 8.5.6.4.3 Market size and forecast, by Therapeutic Indications
- 8.5.6.4.4 Market size and forecast, by Dosage Forms
CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
CHAPTER 10: COMPANY PROFILES
- 10.1 Hologic, Inc
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 Koninklijke Philips N.V.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 Quest Diagnostics Incorporated
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 Siemens Medical Solutions USA, Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 bioMerieux SA
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Abbott
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 BD
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Cardinal Health, Inc.
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 F. Hoffmann-La Roche Ltd
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 General Electric Company
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments